PL2649068T3 - Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX - Google Patents

Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX

Info

Publication number
PL2649068T3
PL2649068T3 PL11804810T PL11804810T PL2649068T3 PL 2649068 T3 PL2649068 T3 PL 2649068T3 PL 11804810 T PL11804810 T PL 11804810T PL 11804810 T PL11804810 T PL 11804810T PL 2649068 T3 PL2649068 T3 PL 2649068T3
Authority
PL
Poland
Prior art keywords
oxazolyl
receptor agonists
alx receptor
methylether derivatives
methylether
Prior art date
Application number
PL11804810T
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL2649068T3 publication Critical patent/PL2649068T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11804810T 2010-12-07 2011-12-06 Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX PL2649068T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010055616 2010-12-07
PCT/IB2011/055487 WO2012077049A1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists
EP11804810.7A EP2649068B1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
PL2649068T3 true PL2649068T3 (pl) 2015-03-31

Family

ID=45444667

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11804810T PL2649068T3 (pl) 2010-12-07 2011-12-06 Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX

Country Status (19)

Country Link
US (1) US8846733B2 (pl)
EP (1) EP2649068B1 (pl)
JP (1) JP5923107B2 (pl)
KR (1) KR101864463B1 (pl)
CN (1) CN103261194B (pl)
AR (1) AR084173A1 (pl)
AU (1) AU2011340146B2 (pl)
CA (1) CA2816376C (pl)
CY (1) CY1116004T1 (pl)
DK (1) DK2649068T3 (pl)
ES (1) ES2526132T3 (pl)
HR (1) HRP20150049T1 (pl)
MX (1) MX2013006418A (pl)
PL (1) PL2649068T3 (pl)
PT (1) PT2649068E (pl)
RU (1) RU2588567C2 (pl)
SI (1) SI2649068T1 (pl)
TW (1) TWI523853B (pl)
WO (1) WO2012077049A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
WO2015007830A1 (en) 2013-07-18 2015-01-22 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
BR112016011755B1 (pt) 2013-11-28 2023-05-02 Kyorin Pharmaceutical Co., Ltd Derivado de ureia ou sal farmacologicamente aceitável do mesmo, seu uso e composição farmacêutica que os compreende
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
BR112017024966A2 (pt) 2015-05-27 2018-08-07 Kyorin Seiyaku Kk derivado de ureia ou sal farmacologicamente aceitável do mesmo
CA3055093A1 (en) * 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
EP1319657A4 (en) 2000-09-22 2005-03-02 Nihon Nohyaku Co Ltd N- (4-PYRAZOLYL AMIDE) DERIVATIVES, CHEMICALS FOR AGRICULTURAL AND HORTICULTURAL USE AND APPLICATIONS THEREOF
WO2003082314A2 (en) 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
JP2009514858A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
HUE025137T2 (en) 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
HRP20130972T1 (hr) 2009-05-18 2013-11-22 Actelion Pharmaceuticals Ltd. Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti
CN101909306A (zh) * 2009-06-08 2010-12-08 中兴通讯股份有限公司 中继站管理方法及基站
RU2544862C2 (ru) 2009-06-09 2015-03-20 Актелион Фармасьютиклз Лтд Фторированные аминотриазольные производные
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物

Also Published As

Publication number Publication date
WO2012077049A1 (en) 2012-06-14
KR101864463B1 (ko) 2018-06-04
JP5923107B2 (ja) 2016-05-24
CA2816376C (en) 2018-11-20
CN103261194A (zh) 2013-08-21
HRP20150049T1 (hr) 2015-02-27
EP2649068B1 (en) 2014-10-29
CA2816376A1 (en) 2012-06-14
SI2649068T1 (sl) 2015-01-30
KR20130133240A (ko) 2013-12-06
TW201305151A (zh) 2013-02-01
PT2649068E (pt) 2014-12-23
RU2588567C2 (ru) 2016-07-10
MX2013006418A (es) 2013-07-15
AR084173A1 (es) 2013-04-24
JP2013544878A (ja) 2013-12-19
CN103261194B (zh) 2016-02-24
DK2649068T3 (en) 2014-12-08
US20130261159A1 (en) 2013-10-03
AU2011340146B2 (en) 2016-05-19
EP2649068A1 (en) 2013-10-16
CY1116004T1 (el) 2017-01-25
RU2013130879A (ru) 2015-01-20
US8846733B2 (en) 2014-09-30
AU2011340146A1 (en) 2013-07-25
TWI523853B (zh) 2016-03-01
ES2526132T3 (es) 2015-01-07

Similar Documents

Publication Publication Date Title
SI2649068T1 (sl) Derivati oksazolil-metiletra kot agonisti alx-receptorja
IL222646A0 (en) N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
ZA201208447B (en) Indoles
EP2646020A4 (en) INDOLES
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
GB201410398D0 (en) Muscarinic m1 receptor agonists
IL229320A0 (en) History of 3-spirocyclic piperidines as ghrelin receptor agonists
EP2569324A4 (en) Aminoglycoside DERIVATIVES
EP2616477A4 (en) 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS
GB2490849B (en) Di-aspirin derivatives
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
IL225393A0 (en) History of Indole
GB201116152D0 (en) Cannabinoid-2-receptor agonists
GB2485874B (en) Beam hanger
TWM387187U (en) Monitor hanging structure
GB201116151D0 (en) Cannabinoid-2-receptor agonists
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
GB201004821D0 (en) Cylinder pivoting device
HK1186116A (en) Microcrystalline y receptor agonists
TWM402665U (en) Improved structure for hanger
TWM385717U (en) Monitor adjustment structure